Wanbang Pharmaceutical Co., Ltd.

Legal Opinion Letter from Anhui Chengyi Law Firm Regarding the 2025 Annual Shareholders' Meeting of Anhui Wanbang Pharmaceutical Technology Co., Ltd.

Announcement of the 2025 Annual Shareholders' Meeting Resolutions

Continuous supervision tracking report for Anhui Wanbang Pharmaceutical Technology Co., Ltd. for 2025

On-site inspection report of continuous supervision for Anhui Wanbang Pharmaceutical Technology Co., Ltd. for 2025

Report on the continuous supervision training situation of Anhui Wanbang Pharmaceutical Technology Co., Ltd. for 2025

Announcement regarding the holding of the 2025 annual performance briefing

Beijing Jiayuan Law Firm's Legal Opinion on the Unachieved Vesting Conditions and Invalidated Restricted Stock Related Matters of Anhui Wanbang Pharmaceutical Technology Co., Ltd.'s 2025 Restricted Stock Incentive Plan

Independent Director Work Report for the Year 2025 (Jiang Baohong) - Resigned

Independent Director Work Report for the Year 2025 (Yin Zongcheng) - Resigned

Independent Director Work Report for the Year 2025 (Zhang Hongbin)

Independent Director Work Report for the Year 2025 (Zhuo Min)

Guolian Minsheng Securities Underwriting and Sponsorship Co., Ltd. Verification Opinion on Anhui Wanbang Pharmaceutical Technology Co., Ltd.'s Self-Evaluation Report on Internal Control for the Year 2025

Internal Control Audit Report for the Year 2025

Self-Evaluation Report on Internal Control for the Year 2025

Related Party Transaction Management System

Management System for Insider Information Registrants

Internal Audit System

Information Disclosure Management System

Announcement on the Compensation Plan for Directors and Senior Management for the Year 2026

Announcement on the Provision for Credit Impairment and Asset Impairment for the Year 2025

Notice of the 2025 Annual Shareholders' Meeting

Announcement of the resolution of the fifth meeting of the third board of directors

Announcement on the 2025 profit distribution and capital reserve fund transfer to increase share capital plan

Q1 2026 Report

Special report on the storage, management, and use of raised funds for 2025

Guolian Minsheng Securities Underwriting and Sponsorship Co., Ltd. on the verification opinion regarding Anhui Wanbang Pharmaceutical Technology Co., Ltd.'s 2025 annual raised funds storage and usage

Verification report on the annual storage, management, and use of raised funds

Report from the Board's Audit Committee on the evaluation of the accounting firm's performance in 2025 and the fulfillment of supervisory responsibilities

Special explanation on non-operating fund occupation and other related fund transactions for 2025

Summary table of non-operating fund occupation and other related fund transactions for 2025

Board's special opinion on the independence of independent directors

2025 Annual Audit Report

2025 Annual Report

2025 Annual Report Summary

Announcement on invalidating part of the granted but unvested and reserved restricted stocks

Announcement on Changing the Continuous Supervision Sponsor Representative

Progress Announcement on Using Part of the Idle Raised Funds (Including Over-raised Funds) and Idle Self-owned Funds to Purchase Cash Management Products for Redemption and Continued Purchase of Cash Management Products